5th STING And TLR-Targeted Therapies Summit 2024 Sheraton Mission Valley San Diego Hotel, San Diego

The innate immune system is increasingly being recognised as a target for a range of exciting applications with high unmet need, from those difficult to treat cancers to infectious and inflammatory disease.

The past year has seen a mix of ups and downs for this space, with several companies entering the clinic, emerging new modalities of STING/TLR agonists and on the other side some clinical setbacks.

The 5th Annual STING and TLR Targeted Therapies Summit returns at a crucial time to unpick the lessons of the past year and finally unleash the well-recognised potential of innate immunotherapy.

In this dynamic field which continuously sees new approaches, keep track of all the goings on within industry, learn the best approach for selecting the right patient population and how to strike that ever tricky balance of safety and efficacy.

This meeting covers everything from early discovery to clinical trial rationale across the innate immune pathway including TLR, STING and broader innate immune system targets like PTPN2/PTPN1 and RNA modifying enzymes, alongside evaluating the rationale for combination approaches with checkpoint inhibitors and beyond.

This meeting will once again converge the key players in STING/TLR and beyond, with actionable insights to unlock the potential of harnessing the innate immune system to meet unmet needs.